RICHARD CARL HARVEY
Pilots at Kiva Ln, Placitas, NM
License number
New Mexico A4184444
Issued Date
Jun 2015
Expiration Date
Jun 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
4 Kiva Ln, Placitas, NM 87043
Professional information
Identification Of Novel Subgroups Of High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia, Outcome Correlations And Diagnostic And Therapeutic Methods Related To Same
US Patent:
8568974, Oct 29, 2013
Filed:
Nov 14, 2008
Appl. No.:
12/734542
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Richard Harvey - Placitas NM, US
George S. Davidson - Albuquerque NM, US
Xuefei Wang - Albuquerque NM, US
Susan R Atlas - Albuquerque NM, US
Edward J. Bedrick - Albuquerque NM, US
Iming L. Chen - Albuquerque NM, US
Richard Harvey - Placitas NM, US
George S. Davidson - Albuquerque NM, US
Xuefei Wang - Albuquerque NM, US
Susan R Atlas - Albuquerque NM, US
Edward J. Bedrick - Albuquerque NM, US
Iming L. Chen - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
Sandia Corporation - Albuquerque NM
Sandia Corporation - Albuquerque NM
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 61, 435 71
Abstract:
The present invention relates to the identification of genetic markers patients with high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients.
Gene Expression Classifiers For Relapse Free Survival And Minimal Residual Disease Improve Risk Classification And Outcome Prediction In Pediatric B-Precursor Acute Lymphoblastic Leukemia
US Patent:
2011023, Sep 22, 2011
Filed:
Nov 16, 2009
Appl. No.:
12/998474
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Richard Harvey - Placitas NM, US
Huining Kang - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Xuefei Wang - Creve Coeur MO, US
Susan R. Atlas - Albuquerque NM, US
I-Ming Chen - Albuquerque NM, US
Richard Harvey - Placitas NM, US
Huining Kang - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Xuefei Wang - Creve Coeur MO, US
Susan R. Atlas - Albuquerque NM, US
I-Ming Chen - Albuquerque NM, US
International Classification:
C40B 40/06, C12Q 1/68, G01N 33/566, C12Q 1/44, C12Q 1/527, C12Q 1/48, G01N 33/573
US Classification:
506 16, 435 618, 435 617, 435 616, 435 61, 435 792, 435 19, 435 4, 435 15, 435 613, 435 71, 436501
Abstract:
The present invention relates to the identification of genetic markers patients with leukemia, especially including acute lymphoblastic leukemia (ALL) at high risk for relapse, especially high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients.
Outcome Prediction And Risk Classification In Childhood Leukemia
US Patent:
2006006, Mar 23, 2006
Filed:
Dec 5, 2003
Appl. No.:
10/729895
Inventors:
Cheryl Willman - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George Davidson - Albuquerque NM, US
Shawn Martin - Albuquerque NM, US
Susan Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard Harvey - Placitas NM, US
David Haaland - Albuquerque NM, US
Jeffrey Potter - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George Davidson - Albuquerque NM, US
Shawn Martin - Albuquerque NM, US
Susan Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard Harvey - Placitas NM, US
David Haaland - Albuquerque NM, US
Jeffrey Potter - Albuquerque NM, US
International Classification:
C12Q 1/68, C07H 21/04, C12P 21/06, C12N 15/09, C07K 14/705
US Classification:
435006000, 435069100, 435320100, 435325000, 530350000, 536023200
Abstract:
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
Outcome Prediction And Risk Classification In Childhood Leukemia
US Patent:
2009020, Aug 13, 2009
Filed:
Jun 8, 2007
Appl. No.:
11/811436
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George S. Davidson - Albuquerque NM, US
Shawn B. Martin - Albuquerque NM, US
Susan R. Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan J. Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard C. Harvey - Placitas NM, US
David M. Haaland - Albuquerque NM, US
Jeffrey W. Potter - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George S. Davidson - Albuquerque NM, US
Shawn B. Martin - Albuquerque NM, US
Susan R. Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan J. Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard C. Harvey - Placitas NM, US
David M. Haaland - Albuquerque NM, US
Jeffrey W. Potter - Albuquerque NM, US
International Classification:
A61K 38/17, C12N 15/12, C07H 21/04, C07K 14/47, A61K 31/711, A61P 35/02, C12N 5/10, C12N 15/85, C12Q 1/68, G01N 33/566
US Classification:
514 12, 536 235, 536 245, 530350, 4353201, 435 6, 435 71, 514 44, 435325
Abstract:
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.